# A Study to Learn About the Study Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People With ER+/HER2- Advanced Breast Cancer in China

> **NCT05732428** · PHASE1 · COMPLETED · sponsor: **Pfizer** · enrollment: 9 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** ARV-471

## Key facts

- **NCT ID:** NCT05732428
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-02-20
- **Primary completion:** 2024-03-29
- **Final completion:** 2024-11-01
- **Target enrollment:** 9 (ACTUAL)
- **Last updated:** 2025-01-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05732428

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05732428, "A Study to Learn About the Study Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People With ER+/HER2- Advanced Breast Cancer in China". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT05732428. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*